news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
The 4th Annual North America Microbiome Congress in Washington DC, by Kisaco Research, has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require an insight into the latest microbiome research, clinical trials and collaborative partnerships.
More information on the event may be found here
